Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Levi Strauss & Co. (LEVI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Levi Strauss & Co. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Levi Strauss & Co. trades at $24.27 (market cap $9.36B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.3× Levi Strauss & Co.'s market cap, and Levi Strauss & Co. pays a 2.63% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | LEVI | |
|---|---|---|
Market Cap | $39.89B | $9.36B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $24.83 |
52-Week Low | $278.09 | $17.92 |
Enterprise Value | $38.15B | $10.67B |
Dividend Yield | — | 2.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Levi Strauss (LEVI) trades at $24.31, up 2.02% today, showing strong fundamental performance with consistent earnings beats and robust profitability metrics. The company recently raised its dividend and full-year guidance following Q2 2026 results, demonstrating confidence in its digital strategy and direct-to-consumer growth. Technical indicators show mixed signals with bearish overall momentum but strong support at $23. Analyst consensus remains overwhelmingly bullish with an 83% buy rating and $28 price target, representing 15% upside potential.
LEVI presents a compelling investment case with strong fundamentals, consistent earnings outperformance, and positive business momentum. Key opportunities include the successful digital transformation, expanding direct-to-consumer sales, and dividend growth. Risks include tariff pressures, foreign exchange volatility, and competitive retail landscape. The stock offers attractive valuation with 15% upside to consensus target, supported by strong cash flow generation and improving balance sheet metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →
